• Produktbild: Peritoneal Carcinomatosis: Drugs and Diseases
  • Produktbild: Peritoneal Carcinomatosis: Drugs and Diseases
Band 81

Peritoneal Carcinomatosis: Drugs and Diseases

Fr. 241.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

16.09.2011

Herausgeber

Paul H. Sugarbaker

Verlag

Springer Us

Seitenzahl

288

Maße (L/B/H)

25.4/17.8/1.6 cm

Gewicht

547 g

Auflage

Softcover reprint of the original 1st edition 1996

Sprache

Englisch

ISBN

978-1-4612-8530-4

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

16.09.2011

Herausgeber

Paul H. Sugarbaker

Verlag

Springer Us

Seitenzahl

288

Maße (L/B/H)

25.4/17.8/1.6 cm

Gewicht

547 g

Auflage

Softcover reprint of the original 1st edition 1996

Sprache

Englisch

ISBN

978-1-4612-8530-4

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Peritoneal Carcinomatosis: Drugs and Diseases
  • Produktbild: Peritoneal Carcinomatosis: Drugs and Diseases
  • Foreword; A. Cohen. Preface; P.H. Sugarbaker. Section I: Pharmacology. 1. Intraperitoneal taxol; M. Markman. 2. Early postoperative intraperitoneal adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma; P.H. Sugarbaker. 3. Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis; A. Stephens, et al. 4. Intraperitoneal regional chemotherapy with mitoxantrone; K. Link, et al. 5. Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin; H.R. Alexander, D.L. Fraker. 6. Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C; V. Fernandez-Trigo, et al. Section II: Disease states. 7. Pathobiology of peritoneal carcinomatosis from ovarian malignancy; T.A. Sugarbaker, et al. 8. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent rectosigmoid cancer; P.H. Sugarbaker. 9. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy; P.H. Sugarbaker. 10. Pseudomyxoma peritonei; P.H. Sugarbaker. 11. Clinical determinants of treatment failures after cytoreductive surgery and intraperitoneal chemotherapy in patients with pseudomyxoma peritonei; V. Fernandez-Trigo, et al. 12. Recurrent intraabdominal cancer causing intestinal obstruction: Washington Hospital Center experience with 42 patients managed by surgery and intraperitoneal chemotherapy; A.M. Averbach, P.H. Sugarbaker. 13. Peritoneal carcinomatosis: Natural history and rational therapeutic interventions using intraperitoneal chemotherapy; P.H. Sugarbaker. 14. Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin c combined with surgery for patients with advanced gastric cancer; S. Fujimoto, et al. 15. Intraperitoneal 5-fluoracil and mitomycin c as an adjuvant to resectable gastric cancer: a status report; W. Yu. 16. Mechanism and treatment of peritoneal carcinomatosis: Intraperitoneal chemotherapy with mitomycin c bound to carbon particles; T. Takahashi, et al. 17. Peritoneal mesothelioma: treatment approach based on natural history; A.M. Averbach, P.H. Sugarbaker. Pathology of peritoneal mesothelioma; M.E. Kass. Rationale for intraperitoneal chemotherapy in the treatment of adenocarcinoma of the pancreas; S.E. Ettinghausen. Heated intraperitoneal mitomycin c infusion treatment for patients with gastric cancer and peritoneal metastasis; S. Fujimoto, et al. Peritoneal carcinomatosis from adenocarcinoma of the colon; M.E.T. Schellinx, et al.